U.S. License Holder:

Janssen Biotech

Date of License:

July-13-2017

FDA-Approved Indications

TREMFYA (guselkumab) is an interleukin-23 blocker indicated for the treatment of:

Adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy;

Adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis;

Adults with moderately to severely active ulcerative colitis;

Adults with moderately to severely active Crohn's disease.